OtherMutsuki Takano was appointed as Chief Financial Officer (CFO)
Co-DevelopmentA clinical research plan to transplant iPSC-derived cardiomyocyte spheroids into patients with severe heart failure at Keio University, our research collaborator, was approved by Ministry of Health, Labor and Welfare.
OtherTakehiko Kaneko was appointed as Chief Medical Officer (CMO)
PRAnnounced Capital and Business Alliance with MEDIPAL HOLDINGS
PRAnnounced Capital Alliance with ITOCHU CHEMICAL FRONTIER
OtherKay Deguchi was appointed as Independent Director
MediaLinks of Keiichi Fukuda’ interviews were posted at CEO Profile.
PRHeartseed raises $26 Million in Series B Funding
OtherAkira Fujiyoshi was appointed as External Auditor
Co-DevelopmentOur research partner, Keio Univ. applied for permission to conduct FIH of iPSC-derived CMs transplant to patients with DCM.